These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 31419313)

  • 21. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
    Cohen A; Kamanda-Kosseh M; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; Bucovsky M; Stubby J; Shane E
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4208-14. PubMed ID: 26358172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation.
    Anastasilakis AD; Polyzos SA; Makras P; Trovas G; Yavropoulou MP; Tournis S
    J Clin Densitom; 2021; 24(4):591-596. PubMed ID: 33541775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study comparing daily teriparatide with monthly cycles of teriparatide and raloxifene.
    Goel H; Libber J; Borchardt G; Krueger D; Binkley N
    Arch Osteoporos; 2021 Apr; 16(1):70. PubMed ID: 33856570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
    Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
    Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
    [No Abstract]   [Full Text] [Related]  

  • 32. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
    Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
    Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
    Minne H; Audran M; Simões ME; Obermayer-Pietsch B; Sigurðsson G; Marín F; Dalsky GP; Nickelsen T;
    Curr Med Res Opin; 2008 Nov; 24(11):3117-28. PubMed ID: 18838053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study).
    Tsai JN; Uihlein AV; Burnett-Bowie SM; Neer RM; Derrico NP; Lee H; Bouxsein ML; Leder BZ
    J Clin Endocrinol Metab; 2016 May; 101(5):2023-30. PubMed ID: 26964731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis.
    Gonnelli S; Martini G; Caffarelli C; Salvadori S; Cadirni A; Montagnani A; Nuti R
    Osteoporos Int; 2006 Oct; 17(10):1524-31. PubMed ID: 16767526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.